These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The nocebo effect challenges the non-medical infliximab switch in practice. Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188 [TBL] [Abstract][Full Text] [Related]
23. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol. Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737 [TBL] [Abstract][Full Text] [Related]
24. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Sidiropoulos P; Kritikos HD; Siakka P; Mamoulaki M; Kouroumali H; Voudouris K; Boumpas DT Clin Exp Rheumatol; 2005; 23(4):513-6. PubMed ID: 16095121 [TBL] [Abstract][Full Text] [Related]
25. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Bonafede M; Joseph GJ; Princic N; Harrison DJ J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of reducing duration of infliximab infusion. Fukuyo S; Saito K; Yamaoka K; Sawamukai N; Hirata S; Nawata M; Iwata S; Tanaka Y Mod Rheumatol; 2014 Mar; 24(2):275-80. PubMed ID: 24251990 [TBL] [Abstract][Full Text] [Related]
27. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133 [TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538 [TBL] [Abstract][Full Text] [Related]
29. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. Fitzcharles MA; Clayton D; Ménard HA J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146 [TBL] [Abstract][Full Text] [Related]
30. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Zheng J; Gao Y; Ding Y Dermatol Ther; 2019 Nov; 32(6):e13132. PubMed ID: 31631466 [TBL] [Abstract][Full Text] [Related]
31. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease. Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793 [TBL] [Abstract][Full Text] [Related]
33. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700 [TBL] [Abstract][Full Text] [Related]
34. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs. Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001 [TBL] [Abstract][Full Text] [Related]
36. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489 [TBL] [Abstract][Full Text] [Related]
37. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Tenga G; Goëb V; Lequerré T; Bacquet-Deschryver H; Daragon A; Pouplin S; Lanfant-Weybel K; Le Loët X; Dieu B; Vittecoq O Joint Bone Spine; 2011 Jan; 78(1):50-5. PubMed ID: 20646950 [TBL] [Abstract][Full Text] [Related]